Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT03261791
Phase
PHASE2
Status
Unknown

Conditions

  • Carcinoma, Hepatocellular

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib mesylate tablets 500 mg po qd.

Study Details

In this phase 2 study, we aim to evaluate the effects and safety of adjuvant apatinib therapy for the patients who underwent R0 resection for hepatocellular carcinoma with portal vein tumor thrombus.

Key Dates

Start date
Jul 20, 2017
Status verified
Aug 2017
Primary completion
Jan 20, 2020
Completion
Apr 20, 2020

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib
    Apatinib mesylate tablets 500 mg po qd.

Primary Outcome Measure

recurrence-free survival [ Time Frame: 24 months ]

Central Contacts

Related Studies